top of page

NICE consultation on Integrated Topic Prioritisation and Strategic Principles – Cancer52’s response 

In April 2024, Cancer52 submitted a response on National Institute for Health and Care Excellence (NICE) consultation on its new approach to prioritising guidance.

Cancer52’s response confirmed benefits of the proposed single prioritisation board and welcomed inclusion of strategic principles for rare diseases, as well as highlights concerns about potential lack of appeal process and how the highly specialised technology programme works for rare and less common cancers. 



The consultation closed on 4th April 2024, more information is available on the NICE website.


bottom of page